Related Experiment Videos
Cutaneous leiomyomas lack estrogen and progesterone receptor immunoreactivity
K M McGinley1, S Bryant, A A Kattine
1Department of Pathology, University of Tennessee Medical Center at Knoxville 37920, USA.
Abstract:
Gonadotropin-releasing hormone analog therapy is useful in treating uterine and some extrauterine smooth muscle tumors. These smooth muscle tumors have been demonstrated to have estrogen receptor and progesterone receptor immunoreactivity. The estrogen receptor and progesterone receptor immunoreactivity of smooth muscle tumors of the skin has not been reported. We evaluated 15 examples of cutaneous leiomyomas for estrogen receptor and progesterone receptor with ER-1D5 antibody and PGR-1A6 antibody. None of the 15 cutaneous leiomyomas demonstrated positive staining by this method. The tumorigenesis of cutaneous leiomyomas does not appear to be related to estrogen or progesterone receptor-mediated effects.
Insights
Gonadotropin-releasing hormone analog therapy is effective for uterine smooth muscle tumors. However, cutaneous leiomyomas (skin smooth muscle tumors) do not show estrogen or progesterone receptor activity, suggesting different growth mechanisms.
Area of Science:
- Dermatology
- Oncology
- Endocrinology
Background:
- Gonadotropin-releasing hormone (GnRH) analog therapy benefits uterine and some extrauterine smooth muscle tumors.
- These tumors often exhibit estrogen receptor (ER) and progesterone receptor (PR) immunoreactivity.
- The receptor status of cutaneous smooth muscle tumors remains largely uninvestigated.
Purpose of the Study:
- To investigate the presence of estrogen receptor (ER) and progesterone receptor (PR) in cutaneous leiomyomas.
- To determine if ER or PR signaling pathways are involved in the development of skin leiomyomas.
Main Methods:
- Evaluated 15 cutaneous leiomyoma samples.
- Utilized ER-1D5 antibody for estrogen receptor assessment.
- Employed PGR-1A6 antibody for progesterone receptor assessment.
Main Results:
- None of the 15 cutaneous leiomyoma samples showed positive staining for estrogen receptors.
- None of the 15 cutaneous leiomyoma samples showed positive staining for progesterone receptors.
- This indicates a lack of ER and PR expression in these skin tumors.
Conclusions:
- Cutaneous leiomyomas do not appear to be driven by estrogen or progesterone receptor-mediated pathways.
- The tumorigenesis of skin leiomyomas likely involves different molecular mechanisms compared to uterine leiomyomas.
- This finding may have implications for treatment strategies for skin leiomyomas.